APLS
Price
$19.54
Change
+$0.09 (+0.46%)
Updated
Nov 20 closing price
Capitalization
2.47B
103 days until earnings call
Intraday BUY SELL Signals
ORMP
Price
$2.42
Change
-$0.07 (-2.81%)
Updated
Nov 20 closing price
Capitalization
96.32M
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APLS vs ORMP

Header iconAPLS vs ORMP Comparison
Open Charts APLS vs ORMPBanner chart's image
Apellis Pharmaceuticals
Price$19.54
Change+$0.09 (+0.46%)
Volume$2.28M
Capitalization2.47B
Oramed Pharmaceuticals
Price$2.42
Change-$0.07 (-2.81%)
Volume$115.73K
Capitalization96.32M
APLS vs ORMP Comparison Chart in %
APLS
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
APLS vs. ORMP commentary
Nov 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and ORMP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 21, 2025
Stock price -- (APLS: $19.54 vs. ORMP: $2.42)
Brand notoriety: APLS and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 86% vs. ORMP: 77%
Market capitalization -- APLS: $2.47B vs. ORMP: $96.32M
APLS [@Biotechnology] is valued at $2.47B. ORMP’s [@Biotechnology] market capitalization is $96.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.15B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 5 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 5 bearish.
  • ORMP’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ORMP is a better buy in the short-term than APLS.

Price Growth

APLS (@Biotechnology) experienced а -1.36% price change this week, while ORMP (@Biotechnology) price change was +0.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.65%. For the same industry, the average monthly price growth was -7.08%, and the average quarterly price growth was +60.39%.

Reported Earning Dates

APLS is expected to report earnings on Mar 04, 2026.

ORMP is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (-1.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.47B) has a higher market cap than ORMP($96.3M). APLS has higher P/E ratio than ORMP: APLS (54.28) vs ORMP (2.42). ORMP YTD gains are higher at: 0.000 vs. APLS (-38.765). APLS has higher annual earnings (EBITDA): 93.4M vs. ORMP (-22.07M). APLS has more cash in the bank: 479M vs. ORMP (97.9M). ORMP has less debt than APLS: ORMP (912K) vs APLS (475M). APLS has higher revenues than ORMP: APLS (1.02B) vs ORMP (2M).
APLSORMPAPLS / ORMP
Capitalization2.47B96.3M2,567%
EBITDA93.4M-22.07M-423%
Gain YTD-38.7650.000-
P/E Ratio54.282.422,243%
Revenue1.02B2M50,800%
Total Cash479M97.9M489%
Total Debt475M912K52,083%
FUNDAMENTALS RATINGS
APLS vs ORMP: Fundamental Ratings
APLS
ORMP
OUTLOOK RATING
1..100
6581
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5592
PRICE GROWTH RATING
1..100
6543
P/E GROWTH RATING
1..100
50100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for APLS (82) in the Medical Distributors industry. This means that ORMP’s stock grew somewhat faster than APLS’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as APLS (100) in the Medical Distributors industry. This means that ORMP’s stock grew similarly to APLS’s over the last 12 months.

APLS's SMR Rating (55) in the Medical Distributors industry is somewhat better than the same rating for ORMP (92) in the Pharmaceuticals Other industry. This means that APLS’s stock grew somewhat faster than ORMP’s over the last 12 months.

ORMP's Price Growth Rating (43) in the Pharmaceuticals Other industry is in the same range as APLS (65) in the Medical Distributors industry. This means that ORMP’s stock grew similarly to APLS’s over the last 12 months.

APLS's P/E Growth Rating (50) in the Medical Distributors industry is somewhat better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that APLS’s stock grew somewhat faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSORMP
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signal:
Gain/Loss:
ORMP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SIDRX13.41N/A
N/A
Hartford Schroders Intl Multi-Cp Val SDR
SGFCX46.46N/A
N/A
Sparrow Growth C
MMPDX34.32-0.34
-0.98%
NYLI WMC Value Class R6
MKDVX20.83-0.21
-1.00%
BlackRock Equity Dividend K
BRUMX16.62-0.23
-1.36%
MFS Blended Research Value Equity R4

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NEVPF. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+0.46%
NEVPF - APLS
41%
Loosely correlated
N/A
DNLI - APLS
39%
Loosely correlated
+1.42%
VNDA - APLS
39%
Loosely correlated
-5.84%
NUVL - APLS
38%
Loosely correlated
+0.90%
IMVT - APLS
38%
Loosely correlated
-1.60%
More